Amplia Therapeutics Limited (INNMF)
OTCMKTS · Delayed Price · Currency is USD
0.0890
0.00 (0.00%)
Feb 11, 2026, 9:30 AM EST

Amplia Therapeutics Income Statement

Millions AUD. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
Other Revenue
5.013.784.451.191.981.53
5.013.784.451.191.981.53
Revenue Growth (YoY)
46.79%-15.02%274.34%-40.02%29.33%4380.44%
Cost of Revenue
0.30.210.440.310.150.31
Gross Profit
4.713.574.010.881.831.22
Selling, General & Admin
3.162.672.62.21.641.13
Research & Development
9.737.535.84.693.772.21
Operating Expenses
13.0310.378.587.175.473.56
Operating Income
-8.32-6.79-4.57-6.29-3.64-2.34
Interest Expense
-0.01-0.06-0.08-0.05-0-
Interest & Investment Income
0.40.280.150.100
EBT Excluding Unusual Items
-7.93-6.57-4.5-6.24-3.64-2.34
Other Unusual Items
-----0.06
Pretax Income
-7.93-6.57-4.5-6.24-3.64-2.28
Net Income
-7.93-6.57-4.5-6.24-3.64-2.28
Net Income to Common
-7.93-6.57-4.5-6.24-3.64-2.28
Shares Outstanding (Basic)
39430719419414695
Shares Outstanding (Diluted)
39430719419414695
Shares Change (YoY)
75.83%58.35%0.02%33.27%53.71%95.36%
EPS (Basic)
-0.02-0.02-0.02-0.03-0.03-0.02
EPS (Diluted)
-0.02-0.02-0.02-0.03-0.03-0.02
Free Cash Flow
-13.39-6.89-5.13-5.31-4.42-2.92
Free Cash Flow Per Share
-0.03-0.02-0.03-0.03-0.03-0.03
Gross Margin
94.06%94.44%90.07%74.14%92.20%79.65%
Operating Margin
-166.25%-179.51%-102.64%-528.45%-183.72%-152.60%
Profit Margin
-158.45%-173.69%-101.14%-524.80%-183.74%-148.75%
Free Cash Flow Margin
-267.38%-182.04%-115.20%-446.19%-222.68%-190.52%
EBITDA
-8.32-6.78-4.56-6.28-3.64-2.34
EBITDA Margin
-166.19%-179.24%-102.40%--183.56%-152.56%
D&A For EBITDA
00.010.010.0100
EBIT
-8.32-6.79-4.57-6.29-3.64-2.34
EBIT Margin
-166.25%-179.51%-102.64%--183.72%-152.60%
Revenue as Reported
5.44.064.61.291.981.59
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.